Arrowstreet Capital
PLX icon

Arrowstreet Capital’s Protalix BioTherapeutics PLX Stock Holding History

Arrowstreet Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,353
Closed -$85K – 2465
2020
Q4 		$85K Sell
23,353
-22,500
-49% -$80.6K ﹤0.01% 2231
2020
Q3 		$177K Buy
45,853
+11,200
+32% +$40.5K ﹤0.01% 2219
2020
Q2 		$131K Buy
+34,653
New +$118K ﹤0.01% 2204

Other funds holding PLX

PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BCM
Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Arrowstreet Capital's PLX Position: Q1 2021 in Review

Arrowstreet Capital sold out of Protalix BioTherapeutics (PLX) in Q1 2021, closing a stake of 23,353 shares — an estimated $85K sold.

Arrowstreet Capital first reported a position in PLX in Q2 2020 and held it in 3 quarters. The position peaked at $177K in Q3 2020. 38 funds tracked by Wall St. Rank hold PLX as of Q1 2021.

  • Arrowstreet Capital reported no remaining Protalix BioTherapeutics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 23,353 Protalix BioTherapeutics shares in Q1 2021, an estimated $85K.
  • Arrowstreet Capital first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 3 quarters.
  • Arrowstreet Capital's Protalix BioTherapeutics position peaked at $177K in Q3 2020.
  • 38 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.